Please use this identifier to cite or link to this item: https://doi.org/10.1177/20406223221083509
Title: Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials
Authors: Yip, Alicia Swee Yan
Leong, Shariel
Teo, Yao Hao
Teo, Yao Neng
Syn, Nicholas LX
See, Ray Meng
Wee, Caitlin Fern
Chong, Elliot Yeung
Lee, Chi-Hang 
Chan, Mark Y
Yeo, Tiong-Cheng 
Wong, Raymond CC 
Chai, Ping 
Sia, Ching-Hui 
Keywords: Science & Technology
Life Sciences & Biomedicine
Pharmacology & Pharmacy
diabetes mellitus
nondiabetics
serum urate
serum uric acid
sodium-glucose cotransporter-2 (SGLT2) inhibitors
type 2 diabetes mellitus
INADEQUATE GLYCEMIC CONTROL
URIC-ACID TRANSPORT
DOUBLE-BLIND
JAPANESE PATIENTS
LOWERING THERAPY
BLOOD-PRESSURE
EMPAGLIFLOZIN MONOTHERAPY
INSULIN-RESISTANCE
ASIAN PATIENTS
ADD-ON
Issue Date: 1-Mar-2022
Publisher: SAGE PUBLICATIONS LTD
Citation: Yip, Alicia Swee Yan, Leong, Shariel, Teo, Yao Hao, Teo, Yao Neng, Syn, Nicholas LX, See, Ray Meng, Wee, Caitlin Fern, Chong, Elliot Yeung, Lee, Chi-Hang, Chan, Mark Y, Yeo, Tiong-Cheng, Wong, Raymond CC, Chai, Ping, Sia, Ching-Hui (2022-03-01). Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials. THERAPEUTIC ADVANCES IN CHRONIC DISEASE 13. ScholarBank@NUS Repository. https://doi.org/10.1177/20406223221083509
Abstract: Objectives: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been found to reduce serum urate in patients with type 2 diabetes mellitus. To evaluate if this effect applies to both patients with and without diabetes, we conducted a systematic review and meta-analysis of SGLT2 inhibitors on serum urate levels in this population. Methods: Four electronic databases (PubMed, Embase, Cochrane and SCOPUS) were searched on 25 September 2021 for articles published from 1 January 2000 up to 25 September 2021, for studies that examined the effect of SGLT2 inhibitors on serum urate in study subjects. Random-effects meta-analysis was performed, with subgroup analyses on the type of SGLT2 inhibitor agent administered, presence of type 2 diabetes mellitus, presence of chronic kidney disease and drug dose. Results: A total of 43 randomized controlled trials, with a combined cohort of 31,921 patients, were included. Both patients with [−31.48 μmol/L; 95% confidence interval (CI): −37.35 to −25.60] and without diabetes (−91.38 μmol/L; 95% CI: −126.53 to −56.24) on SGLT2 inhibitors had significantly lower urate levels when compared with placebo. This treatment effect was similarly observed across different types of SGLT2 inhibitors. However, in type 2 diabetes mellitus (T2DM) patients with chronic kidney disease, the reduction in serum urate with SGLT2 inhibitors became insignificant (95% CI: −22.17 to 5.94, p < 0.01). Conclusion: This study demonstrated that SGLT2 inhibitors are beneficial in reducing serum urate in patients with and without diabetes. SGLT2 inhibitors could therefore contribute to the general treatment of hyperuricaemia.
Source Title: THERAPEUTIC ADVANCES IN CHRONIC DISEASE
URI: https://scholarbank.nus.edu.sg/handle/10635/219419
ISSN: 2040-6223
2040-6231
DOI: 10.1177/20406223221083509
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes a sy.pdf5.51 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

3
checked on Jan 26, 2023

Page view(s)

69
checked on Jan 26, 2023

Download(s)

2
checked on Jan 26, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.